News summary
Newsletter text
[WuXi Biotech issued an announcement on the Hong Kong Stock Exchange to refute the revised draft bill of the US House of Representatives] May 17doubledoublepoker, WuXi Biotech issued an announcement on the Hong Kong Stock Exchange sayingdoubledoublepoker, the company noted the U.S. House Oversight and Accountability Committee's May 15, 2024 statement on Hdoubledoublepoker.RdoubledoublepokerA meeting was held on issues such as the revised draft bill. The revised draft bill differs in content from previous versions, including deleting content related to company CEOs and adding a non-retroactive "grandfather" clause to provide relevant companies with a transition period until January 1, 2032. WuXi Bio emphasized in the announcement that the revised draft bill will include it in the proposed definition of a biotechnology company of concern, which the company believes is an unreasonable pre-determined designation without due process. As a global biopharmaceutical CRDMO platform, WuXi Biotech neither has a human genomics business nor collects human genome data in any of its global businesses. WuXi Bio reiterated that the company will not pose a security risk to the United States or any other country in the past, present or future.
